<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061853</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN06-LV/RALIB</org_study_id>
    <secondary_id>2007-000152-14</secondary_id>
    <nct_id>NCT01061853</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen</brief_title>
  <acronym>RALIB</acronym>
  <official_title>Efficacy of Topical Rapamycin in Treatment of Chronic Erosive Oral Lichen Planus. Double Blind Randomised Controlled Trial Rapamycin vs Topical Steroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine wether topical rapamycin is more efficient than
      topical steroids in the treatment of chronic erosive lichen planus.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Per protocol intermediate analyses of 76 patients and enrollment difficulties.
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COMPLETE CLEARING OF ORAL EROSIVE LESIONS</measure>
    <time_frame>THREE MONTHS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>REGRESSION OF EROSIVE SURFACE AREA</measure>
    <time_frame>THREE MONTHS</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOPICAL SIROLIMUS (RAPAMUNE*)</intervention_name>
    <description>APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE*)1mg/ml bid during 3 months</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOPICAL BETAMETHASONE 0.05%</intervention_name>
    <description>APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE*)0.05% bid during 3 months</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Oral Lichen Planus

          -  Oral Erosive Area More Than 1cm²

          -  Lichen Planus Pathologically Proven

        Exclusion Criteria:

          -  No Previous Treatment by Rapamycin

          -  Non Child Bearing Or Breast Feeding Woman

          -  Patient Who Cannot Be Treated By Rapamycin Or Betamethasone

          -  Chronic Renal Insufficiency (Creatinin Clearance &lt; 40ml/Mn)

          -  Ongoing Treatment By Topical Calcineurin Inhibitors Or Systemic Steroids Or Retinoids
             Or Systemic Immunosuppressors Or Thalidomide Or Griseofulvin Or Antimalarials

          -  Cholesterolemia &gt;7.8 Mmol/L Or Hypertriglyceridemia &gt;3.95mmol/L Non Responsive To
             Medical Treatments

          -  Leucopenia (&lt;3000/Mm3)

          -  Thrombopenia (&lt;100 000/Mm3)

          -  Hypertransaminasemia (&gt;3n)

          -  Hypersensitivity To Macrolides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc VAILLANT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre 1-TOURS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camille FRANCES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre-2 Tenon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scarlette AGBO-GODEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre-3 La Pitié-Salpêtrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liliane LAROCHE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre-4 Avicenne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis PASCAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre-5 St-Louis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel DELAPORTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre-6 Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain TAÏEB, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre-7 Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Philippe DELACOUR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre -8 Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe BERNARD, MD-PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre-9 REIMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of REIMS</name>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <zip>F-51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Avicenne-APHP</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux-St.André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Louis-APHP</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Pitié-Salpêtrière APHP</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tenon-APHP</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>October 15, 2013</last_update_submitted>
  <last_update_submitted_qc>October 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral lichen planus</keyword>
  <keyword>chronic inflammatory</keyword>
  <keyword>mucous membranes</keyword>
  <keyword>erosive lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus</mesh_term>
    <mesh_term>Lichen Planus, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

